ArticleFrontiers in psychiatry2022
What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based
Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Yoga-Based Group Intervention for Inpatients with Schizophrenia Spectrum Disorders-Feasibility, Acceptability, and Preliminary Outcomes of a Rater-Blinded Randomized Controlled Trial.Schizophrenia bulletin · 2026Trial
- Subjective perceptions of negative symptoms among outpatients with schizophrenia and their relatives or caregivers: Definitions, importance, measurement, and desired improvement.Schizophrenia research · 2026Article
- Unexpected resolution of clozapine-induced obsessive-compulsive symptoms with cariprazine augmentation: a case report.BMC psychiatry · 2026Article
- The Clinically Meaningful Score Difference and Meaningful Score Regions in Positive and Negative Syndrome Scale Total Score from Post Hoc Analyses of a Phase 3 Pivotal Clinical Trial of Transdermal Asenapine in Patients with Schizophrenia.Neuropsychiatric disease and treatment · 2026Article
- The assessment of suicidality in psychiatric trials: a protocol for a scoping review.Systematic reviews · 2025Article
- Comparing the Metabolic, Systemic, and Neuropsychiatric Impacts of Olanzapine and Clozapine in Patients with Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Clinical, functional and salivary cortisol level changes in individuals with schizophrenia undergoing cognitive behavioral therapy for psychosis in addition to their usual antipsychotic medication.Comprehensive psychoneuroendocrinology · 2025Article
- Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial.Neuropsychiatric disease and treatment · 2025Article
- The minimal important difference in obsessive-compulsive disorder: An analysis of double-blind SSRI trials in adults.European psychiatry : the journal of the Association of European Psychiatrists · 2024Article
- A Case Report of Treatment With Cariprazine in a Recurrent Psychosis Presumably Induced by Methamphetamine.Cureus · 2023Article
- Crossroads of methodological choices in research synthesis: insights from two network meta-analyses on preventing relapse in schizophrenia.BMJ mental health · 2023Article
- The relationship between mindfulness and empathy with the oxytocinergic system in persons with schizophrenia spectrum disorders - A proof-of-concept randomized controlled trial (OXYGEN).International journal of clinical and health psychology : IJCHPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Minimum clinically important difference (MCID) is a measure that defines the minimum amount of change in an objective score of a clinical test that must be reached for that change to be clinically noticeable. We aimed to find the MCID for patients with predominantly negative symptoms of schizophrenia at its earliest occurrence. Methods: Data of a 26-week long, double-blind study with 454 patients [Positive and Negative Symptom Scale Negative Factor Score (PANSS-FSNS) ≥24, Positive and Negative Symptom Scale Positive Factor Score (PANSS-FSPS) ≤ 19] treated with cariprazine 4.5 mg/d or risperidone 4 mg/d were analyzed. The Clinical Global Impression-Improvement scale was used to quantify minimum improvement (CGI-I = 3) and no clinical change (CGI-I = 4) on the PANSS-FSNS, and the MCID was estimated with the following methods: as the mean PANSS-FSNS changes corresponding to the first instance of minimal improvement across all visits (MCID Results: The MCID Conclusion: Applying different methods led to different results, ranging between 7.3 and 18.5% improvement from the baseline for the MCID at its earliest occurrence in patients with predominantly negative symptoms of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.